Arkadios Wealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Arkadios Wealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.26M	Sell	11,960 -1,577	-12%	-$276K	0.04%	467
2025 Q4	$2.3M	Sell	13,537 -411	-3%	-$63K	0.04%	412
2025 Q3	$1.84M	Buy	13,948 +123	+0.9%	+$14.8K	0.04%	419
2025 Q2	$1.47M	Buy	13,825 +1,115	+9%	+$121K	0.04%	428
2025 Q1	$1.58M	Buy	12,710 +6,899	+119%	+$900K	0.06%	345
2024 Q4	$716K	Buy	+5,811	New	+$685K	0.04%	413
2021 Q4	–	Sell	-25	Closed	-$3K	–	1197
2021 Q3	$3K	Buy	25 +5	+25%	+$755	﹤0.01%	1709
2021 Q2	$3K	Hold	20	–	–	﹤0.01%	1818
2021 Q1	$3K	Hold	20	–	–	﹤0.01%	1470
2020 Q4	$3K	Hold	20	–	–	﹤0.01%	1206
2020 Q3	$3K	Buy	+20	New	+$2.48K	﹤0.01%	907
2020 Q2	–	Sell	-1	Closed	-$100	–	1054
2020 Q1	$100	Buy	+1	New	+$129	﹤0.01%	1145

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Arkadios Wealth Advisors's JAZZ Position: Q1 2026 in Review

Arkadios Wealth Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 12% in Q1 2026, selling an estimated $276K and leaving 11,960 shares worth $2.26M. The position accounts for 0.04% of the portfolio, ranked #467.

Arkadios Wealth Advisors first reported a position in JAZZ in Q1 2020 and has held it in 12 quarters since. The position peaked at $2.3M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Arkadios Wealth Advisors held 11,960 shares of Jazz Pharmaceuticals worth $2.26M as of Q1 2026.
Arkadios Wealth Advisors sold 1,577 Jazz Pharmaceuticals shares in Q1 2026, an estimated $276K.
Jazz Pharmaceuticals made up 0.04% of Arkadios Wealth Advisors's portfolio in Q1 2026, its #467 holding.
Arkadios Wealth Advisors first reported a position in Jazz Pharmaceuticals in Q1 2020 and has held it in 12 quarters since.
Arkadios Wealth Advisors's Jazz Pharmaceuticals position peaked at $2.3M in Q4 2025.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.